CVS Health's poor 2024 performance could be turning around in 2025 with a new CEO and potential rebound, despite challenges.

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

CVS Health Corporation is a vertically integrated healthcare corporation in the United States. The company owns a leading ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...